Denali Therapeutics Inc. DNLI Debt-to-equity

Debt-to-equity at other companies

Eli LillyLLY

1.6×-0.6×

Regeneron PharmaceuticalsREGN

0.1×0.0×

Ultragenyx PharmaceuticalRARE

3.7×—

uniQureQURE

0.2×—

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

Eton Pharmaceuticals, Inc.ETON

1×-0.2×

FAQ

What is Denali Therapeutics Inc.'s debt-to-equity?

Denali Therapeutics Inc. (DNLI) reported debt-to-equity of 0× in Q2 2026.

How has Denali Therapeutics Inc.'s debt-to-equity changed year-over-year?

Denali Therapeutics Inc.'s debt-to-equity decreased by 3.4% year-over-year, from 0× to 0×.

What is the long-term trend for Denali Therapeutics Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s debt-to-equity has grown at a -6.9% compound annual growth rate (CAGR), from 0.1× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.